Plain-English answer
The two-invoice system is China's pharmaceutical distribution reform that generally allows only two invoices between the manufacturer and the public medical institution: one from manufacturer to distributor and one from distributor to hospital. The goal is to reduce multilayer distribution, expose markups, reduce drug prices, and make channels easier to supervise.
Policy context
The policy was issued in January 2017 by the State Council medical reform office and other agencies for drug procurement by public medical institutions. Research describes it as an effort to decrease drug circulation links, make middle price increases transparent, reduce high medicine prices, and ease patient burden. It also changed manufacturer selling expenses and the role of distributors.
Operating model
The two-invoice system forced companies to rethink channel architecture. Multi-tier distributor networks became harder to justify, and manufacturers needed better visibility into price, invoicing, and hospital access. Some companies had to build stronger commercial teams or rely on more capable first-tier distributors. The policy also strengthened compliance scrutiny because invoice trails became more visible.
Strategic reading
For market entry, the two-invoice system means a distributor is not simply a relationship broker. The distributor must be able to invoice properly, serve hospitals directly or through permitted structures, maintain compliance, and handle logistics. Companies should audit channel margins, invoice practices, and hospital account ownership before granting rights.
Decision test
For Two-Invoice System in China, the practical test is whether the analysis identifies the payer rule, hospital incentive, procurement route, affected product category, and implementation level. A page that only says China wants lower prices is not useful. The specific question is who changes behavior, under which rule, with what price, budget, quality, and access consequence.
Implementation detail
Two-Invoice System in China should be read through the full chain of Chinese healthcare finance: policy design, provincial or national implementation, hospital operating response, department-level behavior, and patient access. A reform can lower headline prices while still creating new questions about quality, supply, service availability, hospital incentives, and whether the savings reach patients in the form of usable care. The relevant evidence is therefore not only the announced policy, but also how hospitals, manufacturers, physicians, distributors, and insurers respond after implementation.
For market access, the page is most useful when it separates four layers. The first is the formal rule: who issued it, which products or services it covers, and when it applies. The second is the payment consequence: who loses margin, gains volume, absorbs cost, or changes budget risk. The third is the clinical consequence: whether physicians and hospitals can still choose the product, service, or workflow that fits the patient. The fourth is the commercialization consequence: whether a company should compete, differentiate, localize, redesign the channel, gather new evidence, or avoid the category. Without those layers, payment and procurement reform sounds abstract even though it directly determines adoption.